Ensysce Biosciences received a delisting notice from Nasdaq on August 20, 2024, due to non-compliance with the minimum stockholders' equity requirement of $2.5 million as of June 30, 2024. The company faces potential removal from the Nasdaq Stock Market unless it addresses this listing deficiency.The company plans to request a hearing before the Nasdaq Hearings Panel, which will temporarily stay any delisting action pending the hearing process. While Ensysce intends to explore options to regain compliance, there is no guarantee that the Panel will grant an extension or that the company will successfully meet the listing requirements within any granted extension period.

Ensysce Biosciences received a delisting notice from Nasdaq on August 20, 2024, due to non-compliance with the minimum stockholders' equity requirement of $2.5 million as of June 30, 2024. The company faces potential removal from the Nasdaq Stock Market unless it addresses this listing deficiency.The company plans to request a hearing before the Nasdaq Hearings Panel, which will temporarily stay any delisting action pending the hearing process. While Ensysce intends to explore options to regain compliance, there is no guarantee that the Panel will grant an extension or that the company will successfully meet the listing requirements within any granted extension period.